The aroma chemicals maker delivered a sharp profit beat as operational efficiency and lower costs drove margins back to management's target range.
Privi Speciality Chemicals reported a 30% yearly profit rise in Q2 FY27, with a 42% sequential jump driven by a 310 basis point margin expansion. The company also declared an interim dividend of ₹5 per share.
Privi Speciality Chemicals entered the second quarter with a clear task: translate strong demand into better profitability after a margin dip. The aroma chemicals maker delivered, with profit growth far outpacing sales as operational discipline took hold.
The numbers show a business hitting its stride. Revenue of ₹760 crore rose 12% from a year ago and 14% from the prior quarter. Profit, however, surged 31% year-on-year and a striking 42% sequentially to ₹118 crore. The net profit margin expanded to 15.5%, up 310 basis points from last quarter and 220 from a year ago.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 760.0YoY +12% | 666.2 | 678.7 |
| Profit (₹ Cr) | 118.0YoY +31% | 82.8 | 90.2 |
| Net Profit Margin (%) | 15.5YoY +17% | 12.4 | 13.3 |
The profit beat was powered by a sharp recovery in profitability. According to StockWatch, the consolidated EBITDA margin recovered to around 26.3%, up from 22.9% in Q1 and back near the over-25% level management guides for. Expense growth at 8.2% was nearly half the pace of revenue growth, showing strong operating leverage.
Lower finance costs and a rise in other income also helped. A report from Multibagg.ai notes quarterly finance cost fell to ₹16.9 crore from ₹21.5 crore a year ago. Other income rose sharply to ₹12.7 crore from just ₹0.1 crore in Q2 FY26, providing a further tailwind to the bottom line.
While margin delivery is ahead of plan, the company's medium-term revenue target requires acceleration. Management's '5K:1K' vision aims for ₹5,000 crore revenue and over ₹1,000 crore EBITDA within 3-4 years, implying a 20% annual growth rate. This quarter's 12% yearly growth, though solid, trails that pace.
The bridge to that target is capacity. The Phase-1 expansion to 54,000 MT, initially targeted for September 2026, is now key for near-term volume growth. Phase-2, taking capacity to 66,000 MT by September 2027, is backed by ₹850-900 crore of planned capex. As noted by InvestorFeed, expansion projects are progressing and expected to be ready for commercial operations in the second half of 2028.
The company is also simplifying its structure. Shareholders approved a Scheme of Amalgamation on October 27, merging Privi Fine Sciences and Privi Biotechnologies into the parent to unlock operational synergies.
Key Points
Privi's quarter confirms its ability to defend and expand margins in a stable demand environment. The net profit margin of 15.5% is now above its trailing twelve-month average of 13.4%, suggesting the efficiency gains are material.
The story now pivots to volume. With margins back at target, the focus shifts squarely to the capacity ramp. The delayed Phase-1 expansion must start contributing to topline growth soon for the company to close the gap to its ambitious 20% CAGR target. Investors are weighing strong current execution against the future capital expenditure needed to get there.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.